More than 2.5 MILLION PEOPLE served through education programs, digital resources, and support services

Provided more than 70 FREE PATIENT AND PROFESSIONAL PROGRAMS

Nearly 20,000 PATIENTS, SURVIVORS, AND CAREGIVERS supported through the LRF Helpline

29 NEW GRANTS awarded and more than 51,000 research hours funded—enabling early-career scientists to maintain a research focus on lymphoma

People in all 50 STATES (plus the District of Columbia) and in more than 150 COUNTRIES accessed LRF digital resources

BECAUSE OF SUPPORTERS LIKE YOU, WE MADE GREAT PROGRESS IN 2021
Since our founding, the Lymphoma Research Foundation (LRF) has been leading the way to create a world without lymphoma.

After more than a quarter century, we remain committed to funding the best science and serving the lymphoma community through education, support, and compassion. We are grateful to the scientists who partner with LRF to move the research needle forward and advance our understanding of the more than 100 different lymphoma subtypes. We are thankful for our corporate partners, donors, and volunteers who support the Foundation's vital work and make progress possible.

“The Lymphoma Research Foundation helps advance life-saving research, helping fund crucial clinical trials and research endeavors that have contributed to many FDA approvals and advancement in the field.”

Anita Kumar, MD
Memorial Sloan Kettering Cancer Center,
Two-Time LRF Grantee
Letter from the CEO & Chair of the Board

Dear Friends,

We are excited to share the progress made by the Lymphoma Research Foundation (LRF) over the past year. This report highlights many of the Foundation’s achievements during this time, all made possible by the unwavering commitment of LRF supporters.

But this report is not only a story of progress; it is a story of opportunity and the people behind these accomplishments. Opportunity is a theme that resonates throughout this report and in everything we do. LRF is in constant search of opportunity: The opportunity to help patients and caregivers in need; to support the next generation of lymphoma scientists; and to advance life-saving research. As you will read, we sought to accomplish this important work by prioritizing health equity through Spanish-language programming and scientific workshops addressing the challenges faced by underrepresented populations. As such, we created a collaborative scientific research mentoring program, using our convening power to establish the nation’s only COVID-19 and Lymphoma Panel, and expanded digital programs to better serve lymphoma patients, healthcare professionals, and researchers alike.

The LRF mission to eradicate lymphoma forever is driven by and for people: People who research, treat, and support those affected by this disease. We are fortunate to have trusted supporters and partners who provide resources that enable us to pursue these opportunities and serve those touched by this disease.

With gratitude,

Meghan Gutierrez
Chief Executive Officer

Steven Eichberg
Chair, Board of Directors
OUR MISSION
To eradicate lymphoma and serve all those touched by this disease.

OUR FOCUS
Devoted exclusively to funding lymphoma research and supporting the lymphoma community through evidence-based education, support services, and resources.

Research
Our disease specificity and hyperfocus on finding cures for every type of lymphoma ensure the next generation of cancer researchers dedicate their careers to studying lymphoma.

Education & Support
We lead the way in ensuring patients and their loved ones have the support and knowledge they need to make informed decisions about their care.

Awareness & Advocacy
Awareness and advocacy are vital in our effort to increase the public's understanding of this disease, increase federal investment in lymphoma research, and improve patient outcomes.
“The Lymphoma Research Foundation (LRF), and the work it does, is critical in supporting people with lymphoma and their loved ones, and the next generation of scientists. Although significant progress has been made, we are not curing everybody, nor are we helping everyone to live to their best potential. We need to continue to conduct research until that happens, and LRF is the driving force to accelerating cures as well as ensuring that no one faces this disease alone.”

Sonali M. Smith, MD, FASCO
The University of Chicago
Chair, LRF Scientific Advisory Board
OUR IMPACT

With a patient-focused approach and unique access to lymphoma experts, the Lymphoma Research Foundation (LRF) is the organization of choice for businesses, foundations, and individuals looking to make an impact in the pursuit of cures for lymphoma.

Our exceptional education resources for the lymphoma community and investment in the most promising research have cemented us as a trusted resource and respected partner among lymphoma patients and their loved ones, researchers, clinicians, and policymakers.

“Through the Lymphoma Research Foundation, I’ve learned that sharing my story makes a tremendous impact and is a unique way of addressing the immediate need of someone newly diagnosed—the need for hope. By connecting with patients, I can help calm some of their anxiety. I’ve also learned so much about research. The lymphoma I have is so rare, yet it amazes me the amount of research being done, due largely to the work of LRF. The Foundation saves lives in so many ways.”

Shelia Johnson
Cutaneous T-cell Lymphoma
Survivor
ACHIEVEMENTS
IN 2021

Research

• Funded 29 new grants—including 14 scholars in the newly expanded Lymphoma Scientific Research Mentoring Program (LSRMP)—enabling early-career scientists to maintain a research focus on lymphoma.

• Convened the first-ever Transformed Lymphomas Scientific Workshop, bringing together a select group of experts in chronic lymphocytic leukemia/Richter’s transformation, transformed follicular lymphoma, and transformed marginal zone lymphomas, to discuss pressing issues in research and development of better treatment strategies for patients.

• Established the COVID-19 and Lymphoma Initiative to regularly convene a panel of experts in the fields of lymphoma, epidemiology, infectious disease, and public health to contribute to the body of evidence on this important subject and bring attention to the needs of the lymphoma community.

• Launched the Health Equity Initiative with the goal of removing barriers and creating opportunities so that researchers and clinicians can pursue—and every person can access—quality healthcare.

• Jacob Soumerai, MD, of Massachusetts General Hospital presented data at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition. This study, funded in part by LRF, showed that minimal residual disease (MRD) kinetics is a good predictor of achievement and durability of undetectable MRD with BOVen treatment in patients with chronic lymphocytic leukemia (CLL).

Education & Support

• Served more than 2.5 million people through education programs, digital resources, and support services.

• Launched Lymphoma.org en Espanol and expanded our lymphoma education resources and programming to address the language and ethnic discordance seen in existing disease materials and other resources that create barriers to effective communication of lymphoma information for the Spanish-speaking community.

• Provided more than 70 free patient and professional education programs, ensuring patients and their loved ones have the most up-to-date information on their type of lymphoma, and practicing physicians stay up to date on issues specific to the diagnosis and treatment of their lymphoma patients.

• The LRF Helpline supported nearly 20,000 people, offering patients, survivors, and caregivers resources and services in a critical time of need.

• The Lymphoma Support Network grew to more than 7,000 volunteers who share their lymphoma stories and provide peer support to patients and their loved ones.

Awareness & Advocacy

• Mobilized LRF Advocates to raise their collective voices in support of greater investment in cancer research. Congress listened, allocating $6.56 billion to the National Cancer Institute (NCI)—a $119 million increase over the fiscal year 2020 regular and Cancer Moonshot appropriations.

• Joined blood cancer organizations to urge the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC) to prioritize the COVID-19 vaccination for blood cancer patients and other immunocompromised people.

• Reached more than 30 million people through Light it Red for Lymphoma, our LRF Blood Cancer Awareness Month Initiative.

• More than 3,000 people nationwide joined Team LRF to raise funds to support life-saving research and provide hope to all those impacted by lymphoma.
FINDING OPPORTUNITY: RESEARCH

We are privileged to work with the leading minds in lymphoma research—our elite Scientific Advisory Board (SAB), which guides our research programs. These dedicated experts convene annually to help us find opportunities where the Lymphoma Research Foundation can make the biggest impact—from investing in the best and brightest researchers, to facilitating collaboration and partnerships among academic scientists, clinicians, and government and regulatory agencies to discuss the state of lymphoma research and patient care.

GLOBAL SCIENTIFIC IMPACT

Through our global lymphoma consortia, research initiatives, and scientific workshops, we mobilize the research community to overcome systemic challenges and accelerate the development of new treatments for lymphoma and chronic lymphocytic leukemia (CLL).

In March 2021, we convened experts in the fields of lymphoma, epidemiology, infectious disease, and public health for the inaugural COVID-19 and Lymphoma Panel. The purpose of the panel was to discuss the state of research regarding the COVID-19 vaccine and people with lymphoma. Proceedings from the panel regarding future areas of discovery and scientific research influenced the Centers for Disease Control and Prevention (CDC) vaccine recommendations for immunocompromised people, providing better guidance for lymphoma patients and their loved ones. Due to the astounding impact of the inaugural panel and rapidly shifting pandemic, the COVID-19 and Lymphoma Panel began to meet monthly in Fall 2021 to stay on the cutting edge and ensure the needs of the lymphoma community are met.
Transformed lymphomas are typically associated with the rapid progression of CLL and often have a poor prognosis. The underlying biology of transformation is not fully understood, and there are limited educational resources and clinical trials dedicated to this patient population.

In August 2021, we convened a select group of researchers, regulatory officials, and industry representatives for the inaugural Transformed Lymphomas Scientific Workshop to discuss pressing issues with CLL, Richter’s transformation, transformed follicular lymphoma (FL), and transformed marginal zone lymphoma (MZL). Recommendations from this two-day virtual program will profoundly inform research, the development of better treatment strategies, and educational programming—providing a huge step forward in supporting those impacted by this disease.

In 2021, we awarded 29 research grants, totaling more than $2 million, to early-career scientists—the only private foundation to do so in 2021. Our grantee class represents the world’s leading cancer research institutions in North America, covering various disease subtypes, treatments, and cohorts, including T-cell lymphomas, B-cell lymphomas, adolescent and young adult lymphoma, and chimeric antigen receptor (CAR) T-cell therapy. Among this class are translational researchers in the newly expanded Lymphoma Scientific Research Mentoring Program (LSRMP). The addition of a translational track in the LSRMP will foster and develop the next generation of laboratory and translational researchers, bridge the network among clinical researchers, and provide them with the tools and knowledge needed to develop successful clinical trials in lymphoma.
# Meet Our Grantees

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Focus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pamela B. Allen, MD</td>
<td>Winship Cancer Institute of Emory University</td>
<td>Lymphoma Focus: Mycosis fungoides, primary cutaneous T-cell lymphoma, Sézary syndrome</td>
</tr>
<tr>
<td>Jamie Flerlage, MD</td>
<td>St. Jude Children’s Research Hospital</td>
<td>CAREER DEVELOPMENT AWARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Hodgkin lymphoma, pediatric and adolescent/young adult (AYA) lymphoma</td>
</tr>
<tr>
<td>Tomohiro Aoki, PhD</td>
<td>BC Cancer Research Centre</td>
<td>LRF SCHOLAR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Hodgkin lymphoma</td>
</tr>
<tr>
<td>Elena Battistello, PhD</td>
<td>NYU Grossman School of Medicine</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: T-cell lymphoma</td>
</tr>
<tr>
<td>David A. Bond, MD</td>
<td>The Ohio State University Comprehensive Cancer Center</td>
<td>ERIC COHEN DISTINGUISHED SCHOLAR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>Lydie Debaize, PhD</td>
<td>Dana-Farber Cancer Institute</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: B-cell lymphoma, mantle cell lymphoma</td>
</tr>
<tr>
<td>Kathleen Dixon, PhD</td>
<td>University of Minnesota Twin Cities</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Non-Hodgkin lymphoma, B-cell lymphoma</td>
</tr>
<tr>
<td>Zachary Epstein-Peterson, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>LRF SCHOLAR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: T-cell lymphoma</td>
</tr>
<tr>
<td>Edmond Ferris, PhD</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: B-cell lymphoma, T-cell lymphoma</td>
</tr>
<tr>
<td>Niloufer Khan, MD, MS</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>LRF SCHOLAR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Primary cutaneous T-cell lymphoma, Sézary syndrome</td>
</tr>
<tr>
<td>Rui Guo, MS, PhD</td>
<td>Brigham and Women's Hospital, Harvard Medical School</td>
<td>CAREER DEVELOPMENT AWARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Burkitt lymphoma</td>
</tr>
<tr>
<td>Rosella Marullo, MD, PhD</td>
<td>Weill Cornell Medicine</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>Alexandre Hirayama, MD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Diffuse large B-cell lymphoma, marginal zone lymphoma</td>
</tr>
<tr>
<td>Hannah Isles, PhD</td>
<td>Weill Cornell Medicine</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>P. Connor Johnson, MD</td>
<td>Massachusetts General Hospital Cancer Center</td>
<td>STEPhanie A. Gregory MD, FACP, DISTINGUISHED SCHOLAR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Aggressive non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>Richa Kapoor, PhD</td>
<td>University of Pennsylvania Perelman School of Medicine</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: T-cell lymphoma</td>
</tr>
<tr>
<td>Rui Guo, MS, PhD</td>
<td>Brigham and Women's Hospital, Harvard Medical School</td>
<td>CAREER DEVELOPMENT AWARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Burkitt lymphoma</td>
</tr>
<tr>
<td>Edmond Ferris, PhD</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>POSTDOCTORAL FELLOWSHIP GRANT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: B-cell lymphoma, T-cell lymphoma</td>
</tr>
<tr>
<td>Jamie Flerlage, MD</td>
<td>St. Jude Children’s Research Hospital</td>
<td>CAREER DEVELOPMENT AWARD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphoma Focus: Hodgkin lymphoma, pediatric and adolescent/young adult (AYA) lymphoma</td>
</tr>
</tbody>
</table>
“The Lymphoma Research Foundation (LRF) has been part of my lymphoma journey since day one, and I look forward to helping them make an impact on the lymphoma community. I feel confident the Runge Lymphoma Project’s investment in LRF’s mentoring program will prove dividends in lymphoma research.”

Matt Runge, Founder of the Runge Lymphoma Project
FINDING OPPORTUNITY: COMMUNITY EMPOWERMENT

At the core of our mission is our commitment to empowering patients with the knowledge and support they need to make informed decisions about their care. Just as we’ve found opportunities to connect the scientific community and expand our impact in research, we’ve led the way toward improved education and patient and caregiver support.

In this era of ever-evolving treatment paradigms coupled with the challenges brought by the COVID-19 pandemic, the need to provide support and the latest evidence-based information to patients and their loved ones is even more critical.

EXPANDING REACH THROUGH VIRTUAL PROGRAMMING

Since the onset of the COVID-19 pandemic, we quickly responded to ensure the lymphoma community still had access to the latest research and treatment information related to their disease. In 2021, we offered more than 70 patient and professional education programs virtually, all including critical updates on the COVID-19 virus and vaccines, and we served more than 2 million people through our virtual education programming and digital resources. Our webinar on updates from the 2020 American Society of Hematology (ASH) Meeting and Exposition provided more than 1,000 attendees an opportunity to receive updates on pivotal research studies straight from experts in the field.

CONNECTING THE LYMPHOMA COMMUNITY

A lymphoma diagnosis can bring many emotions and challenges, and we are here to make sure no one goes through their journey alone. In 2021, our Lymphoma Support Network (LSN) grew by more than 20 percent, offering more one-to-one peer support to people with lymphoma and their caregivers. More than 7,000 lymphoma survivors and caregivers are part of our LSN community to connect with others, share their personal stories, and offer emotional support.

EASING THE FINANCIAL BURDEN OF TREATMENT

Compared to 10 years ago, lymphoma patients are receiving more expensive chemotherapy, immunotherapy, and other new treatments. Add the financial challenges the COVID-19 pandemic has wrought, patients and their loved ones are dealing with a financial impact never seen before. In 2021, we provided more than 650 grants through our Patient Aid Grant program, a 50 percent increase over last year. This program is powered entirely through support from individuals and private foundations who want to pay it forward and support patients during a time of need.
Our Lymphoma Support Network grew by more than 20%.

We offered more than 70 patient and professional education programs.

We provided more than 650 grants through our Patient Aid Grant program.
FINDING OPPORTUNITY: HEALTH EQUITY

Achieving health equity requires the removal of barriers and the creation of opportunities so that every person has access to quality healthcare and the means to be as healthy as possible. We have witnessed this firsthand in service to people with lymphoma and their loved ones.

Our Health Equity Initiative aims to address these barriers and champion systemic changes to the way we educate and inform the lymphoma community. Through guidance from our Scientific Advisory Board (SAB) and partnerships with community organizations and corporations, we’ve made great strides in 2021 in delivering excellent and evidence-based information to patients in underrepresented and underserved populations and in fostering a more inclusive research community.

COMMUNITY-BASED, PATIENT-CENTERED EDUCATION

Recognizing that patients rely heavily on information available to them to maintain their health and their families’ health, it is crucial to ensure that such resources are culturally appropriate, produced in multiple languages, and made available to patients and their loved ones where they are and feel most comfortable receiving such information. In 2021, we developed education programs and resources in Spanish, including a website, disease-specific fact sheets, and virtual education programs. These materials help the Spanish-speaking community learn about the diagnosis and treatment of lymphoma from experts and provide access to critical support services, including financial and clinical trial search assistance.
DIVERSITY IN CLINICAL TRIALS

The COVID-19 pandemic showed how various segments of Americans (racial and ethnic minorities, young people, the elderly, etc.) are impacted differently, and so too is the need to prioritize education and opportunities for these groups. This is true in the case of clinical trials, which are critical to advancing new therapies for the treatment of lymphoma. In 2021, we prioritized awareness and education around clinical trials by spotlighting information on the topic and on our multilingual Clinical Trials Information Service in all education programs and materials. As a result, the Clinical Trials Information Service witnessed a 61 percent increase in searches compared to the previous year. In addition to educating patients on clinical trials, we prioritized funding research focused on understanding the drivers of disparities in lymphoma.

REPRESENTATION IN BLOOD CANCER RESEARCH AND CLINICAL CARE

Despite decades of workforce diversity efforts, diversification in medical subspecialties like lymphoma research and clinical care remains a challenge. Long-standing institutional traditions and policies that result in inequity create barriers for underrepresented groups in advancing their medical careers. In 2021, we continued our focus on ensuring the best and the brightest scientists remain in the field of lymphoma research and also on advancing advancing opportunities for early-career scientists. As a result, 60 percent of our 2021 Clinical Career Development Award (CDA) and Postdoctoral Fellowship grantees are women.
The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2021, and 2020 have been derived from Lymphoma Research Foundation’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org/annualreport. The Financial Statements have been audited by KPMG LLP.
## Financial Reports (in thousands) as of June 30, 2021

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$5,490</td>
</tr>
<tr>
<td>Investments</td>
<td>20,747</td>
</tr>
<tr>
<td>Contributions and grants receivable</td>
<td>4,580</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>390</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$31,207</strong></td>
</tr>
</tbody>
</table>

### Liabilities & Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research grants payable</td>
<td>$3,199</td>
</tr>
<tr>
<td>Refundable advances</td>
<td>766</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>412</td>
</tr>
<tr>
<td>Accrued salaries and vacation</td>
<td>211</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$4,588</strong></td>
</tr>
<tr>
<td>Unrestricted net assets</td>
<td>5,562</td>
</tr>
<tr>
<td>Temporarily restricted net assets</td>
<td>21,057</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$26,619</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities &amp; Net Assets</strong></td>
<td><strong>$31,207</strong></td>
</tr>
</tbody>
</table>

## Condensed Statement of Activities (in thousands) as of June 30, 2021

### Unrestricted Contributions & Revenues

<table>
<thead>
<tr>
<th>Description</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special events revenues &amp; contributions</td>
<td>$5,726</td>
</tr>
<tr>
<td>Investments &amp; other income</td>
<td>100</td>
</tr>
<tr>
<td><strong>Contributions &amp; Revenues</strong></td>
<td><strong>$5,826</strong></td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>4,265</td>
</tr>
<tr>
<td><strong>Total Contributions &amp; Revenues</strong></td>
<td><strong>$10,091</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$6,793</td>
</tr>
<tr>
<td>Supporting services</td>
<td>2,420</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$9,213</strong></td>
</tr>
<tr>
<td>Increase in unrestricted net assets</td>
<td>$878</td>
</tr>
<tr>
<td>Increase in temporary restricted net assets</td>
<td>$7,029</td>
</tr>
<tr>
<td><strong>Increase in Net Assets</strong></td>
<td><strong>$7,907</strong></td>
</tr>
</tbody>
</table>
The Lymphoma Research Foundation's volunteer Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts, guides the Foundation's research activities, seeking out the most innovative and promising lymphoma research projects for support.

Fiscal year ending June 30, 2021
BOARD OF DIRECTORS

STEVEN EICHBERG
Chair
Plymouth, MA

JEFF BLOCK
Vice Chair and Treasurer
San Francisco, CA

KIM METCALF
Vice Chair
Landenberg, PA

LEIGH OLSON
Secretary
Miami Beach, FL

MICHAEL AKINYELE
Upper Marlboro, MD

ERIC COHEN
In Memoriam
Chicago, IL

MORTON COLEMAN,
MD Chair, Medical Affiliates Board
New York, NY

KEVIN FENNESSEY
Naples, FL

MICHAEL FROY
Chicago, IL

TOM GOLDSTONE
New York, NY

KEITH HOOGLAND
Glencoe, IL

JOHN LEONARD, MD
Past Chair, Scientific Advisory Board
New York, NY

BOB MCAULEY
Charlottesville, VA

JOHN A. NELSON
Westport, CT

SCOTT PANSKY
Tarzana, CA

STEVEN J. PRINCE
Past Chair
Purchase, NY

MICHAEL WERNER
Immediate Past Chair
Chicago, IL

ANDREW D. ZELENETZ, MD, PhD
Chair, Scientific Advisory Board
New York, NY

MEMBERS EMERITUS

JOSEPH R. BERTINO, MD
In Memoriam
New Brunswick, NJ

ERROL M. COOK
Past Chair
Boca Raton, FL

BARBARA FREUNDLICH
Founder
New York, NY

JERRY FREUNDLICH
Founder and Past Chair
New York, NY

DONNA REINBOLT
Houston, TX

ROBERT WERNER
Aventura, FL

LEADERSHIP DONORS

Thank you to our leadership donors for providing hope to the lymphoma community through their commitment to supporting innovative research and evidence-based educational resources.

ABBVIE, INC
ACROTECH BIOPHARMA, LLC
THE ACTOR’S FUND OF AMERICA
ADAPTIVE BIOTECHNOLOGIES
ADC THERAPEUTICS
AMERICAN BOARD OF INTERNAL MEDICINE
ANONYMOUS
MR. AND MRS. STEVEN ARONOW
ASTRAZENECA
THE DAVID R. AND PATRICIA D. ATKINSON
FOUNDATION
MR. GLENN R. AUGUST
MR. JOHN BALLANTINE
MRS. MARY ELLEN BATZNER AND MR. GERALD D.
BATZNER
MR. AND MRS. MICHAEL BEAURY
BEIGENE
STEVEN BENENSON
MAXA SCHUTZBANK BERID
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)

MR. JEFFREY BLOCK
JULIE BLUME
BRISTOL-MYERS SQUIBB
MR. AND MRS. ROBERT BRITTON
THE BRUNING FOUNDATION
BTG INTERNATIONAL, INC
MRS. CONNIE BULL
MR. SCOTT CARNEY
CELLECTAR BIOSCIENCES, INC
MR. OLIVER CHANG
DR. AND MRS. BRUCE D. CHESON
CHIKE SPRINGER FOUNDATION
BRAD CLARK
CLEARFIELD CAPITAL MANAGEMENT LP
MICHAEL AND PATTY COHEN
MS. JEAN R. COLBERT
JOYCE AND MORTON COLEMAN, MD
SUE AND JIM COLLETTI
CONDON FAMILY FOUNDATION
CONDUIT PHILANTHROPIC FUND

MR. AND MRS. FRED CONROY
GLADYS AND ERROL COOK
MR. AND MRS. LEON COOPERMAN
DAIICHI SANKYO, INC
GLORIA AND SIDNEY DANZIGER FOUNDATION
MR. AND MRS. GARY DAVIS
LAURA DE REITZES
MRS. CORISSA DEROSSE
MR. JONATHAN DIESENHAUS
GAIL AND LARRY DOBOSH
MR. AND MRS. HOWARD C. DRAFT
MARGARET D. DUNSTAN
BREECE AND RANDI EHRENBOURG
JEAN AND STEVEN EICHBERG
ELI LILLY AND COMPANY
EPIZEYE
MR. AND MRS. ROBERT FEILBOGEN
JEFF FELLINGE
THE FERRIDAY FUND CHARITABLE TRUST
MRS. ARLENE FISCHER
Thank you to our Circle of Hope partners, whose monthly support ensures we can respond to the needs of our community and further groundbreaking research year-round.

Thank you to our Mason Society supporters, whose bequests through bequests create a legacy of hope for the lymphoma community.
LRF HELPLINE
800-500-9976 (M-F; 9:30am-7:30pm ET)
helpline@lymphoma.org

To create lasting impact:
please donate at lymphoma.org/donate